Journal of lung cancer最新文献_第7页

The Clinical Approach to Nodular Ground Glass Opacity in the Lung 肺结节性磨玻璃混浊的临床探讨

Journal of lung cancer Pub Date : 2010-06-01 DOI: 10.6058/JLC.2010.9.1.1

C. Lee

{"title":"The Clinical Approach to Nodular Ground Glass Opacity in the Lung","authors":"C. Lee","doi":"10.6058/JLC.2010.9.1.1","DOIUrl":"https://doi.org/10.6058/JLC.2010.9.1.1","url":null,"abstract":"The introduction of low dose chest computed tomography for health screening in Korea has resulted in increased detection of solitary pulmonary nodules, including nodular ground glass opacity. In contrast to the classic solitary pulmonary nodule, nodular ground glass opacity (GGO) has special characteristics especially in Koreans. More than half of nodular GGOs are transient and they are caused by a pulmonary infiltrate of eosinophils. However, persistent nodular GGO (nGGO) showed a high malignant potential such as atypical adenomatous hyperplasia and bronchioloalveolar cell carcinoma. The increasing use of video assisted thoracoscopic surgery (VATS) for diagnosis and treatment is the current trend for managing nodular GGO. Even though lobectomy is still the standard management for malignant nGGO, limited resection (wide wedge resection or segmentectomy) is widely used for the small malignant GGO (Noguchi types A and B). Multifocal nodular GGOs are mostly of a synchronous origin rather than intrapulmonary metastasis. Therefore, aggressive surgical resection is warranted. This review contains the current concepts for managing nodular GGO and it especially focuses on the Korean data. (J Lung Cancer 2010;9(1):1 󰠏 8)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"9 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2010.9.1.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71160545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Small Cell Lung Cancer at Subcarina Presenting as a Metastatic Brain Tumor 隆突下小细胞肺癌表现为转移性脑瘤

Journal of lung cancer Pub Date : 2010-06-01 DOI: 10.6058/JLC.2010.9.1.24

Mi Ae Kim, Eun-Kyung Kim, Ji Hyun Lee, H. Jeong

引用次数: 0

Molecular Diagnosis in Lung Cancer 肺癌的分子诊断

Journal of lung cancer Pub Date : 2010-06-01 DOI: 10.6058/JLC.2010.9.1.9

K. Lee

{"title":"Molecular Diagnosis in Lung Cancer","authors":"K. Lee","doi":"10.6058/JLC.2010.9.1.9","DOIUrl":"https://doi.org/10.6058/JLC.2010.9.1.9","url":null,"abstract":"The advent of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib has opened a new horizon for the therapeutic options for patients with advanced lung cancer. Treatment paradigms are shifting from cytotoxic chemotherapies to molecular-based targeted therapies. The discovery of somatic mutations in the exons 18 to 21 of the tyrosine kinase (TK) domain of EGFR has revolutionized the understanding of EGFR in lung carcinogenesis and this has opened a new era for the importance of predictive biomarkers to select the treatment of choice and for personalized therapy for lung cancer. Three important EGFR assays are used and these include mutational analysis, fluorescence in situ hybridization and immunohistochemistry. EGFR mutation study seems to be the most important biomarker to predict the response to EGFR-TKI, yet technical standardization for analyzing the status of EGFR mutation is the key factor. Therefore, it is important to standardize the approach and decide which assays are best to predict a patient’s response to targeted therapies. It is also essential to determine the most cost-effective way to integrate EGFR molecular assays into clinical practice. This review will address the practical aspects of each of the currently proposed assays that have focused on EFGR mutational analysis and also the other important molecular markers such as k-ras mutation, the EML4-ALK fusion oncogene, ERCC1 and RRM1.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"9 1","pages":"9-14"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2010.9.1.9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71160808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer 贝洛替康和顺铂联合化疗治疗未经治疗的广泛性小细胞肺癌

Journal of lung cancer Pub Date : 2010-06-01 DOI: 10.6058/JLC.2010.9.1.15

Jeong Eun Lee, K. Lee, H. Park, S. Jung, Ju Ock Kim, S. Kim

引用次数: 0

Epitheilioid Trophoblastic Tumor of the Lung: A Case Report 肺上皮样滋养细胞瘤1例报告

Journal of lung cancer Pub Date : 2009-12-01 DOI: 10.6058/JLC.2009.8.2.114

S. Ha, H. Cho, Jae-ik Lee

引用次数: 2

Biomarkers for Lung Cancer 肺癌的生物标志物

Journal of lung cancer Pub Date : 2009-12-01 DOI: 10.6058/JLC.2009.8.2.67

S. Yang

{"title":"Biomarkers for Lung Cancer","authors":"S. Yang","doi":"10.6058/JLC.2009.8.2.67","DOIUrl":"https://doi.org/10.6058/JLC.2009.8.2.67","url":null,"abstract":"Over the last decade, intense interest has been focused on discovery of biomarkers and their clinical uses. Lung cancer biomarker discovery has particular eminence in this field due to its anticipated critical role in risk stratification, early detection, treatm ent selection, prognostication, and m onitoring for recurrence of cancer. Significant progress has been m ade in our understanding of the steps involved in lung carcinogenesis and in development of novel technologies for biomarker discovery. The most active areas of research have been in promoter hypermethylation , proteomics, and genomics. Many investigators have adopted panels of serum biomarkers in an attempt to increase sensitivity. M arkers for identification of lung cancer patients who may benefit from targeted therapy have been developed more rapidly. Development of targeted lung cancer therapy has engendered interest in m arkers for identification of optim al candidates for these therapies. Despite extensive study to date, few have turned out to be useful in the clinic. Even those used in the clinic do not show enough sensitivity, specificity, and reproducibility for general use. All biomar kers identified so far m ust be validated in larger clinical cohorts.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"8 1","pages":"67-77"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2009.8.2.67","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71160325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary Lung Adenocarcinoma Metastasis to the Vagina: A Case Report 原发性肺腺癌转移至阴道1例

Journal of lung cancer Pub Date : 2009-12-01 DOI: 10.6058/JLC.2009.8.2.111

S. Ha, Sanghui Park, E. Cho, Soyi Lim, Jungsuk An

引用次数: 0

Pulmonary Paragonimiasis Mimicking Lung Malignancy 模拟肺部恶性肿瘤的肺吸虫病

Journal of lung cancer Pub Date : 2009-12-01 DOI: 10.6058/JLC.2009.8.2.118

Joon-Suk Choi, I. Oh, Y. Choi, Yong-Soo Kwon, K. S. Kim, S. Lim, Young-chul Kim

{"title":"Pulmonary Paragonimiasis Mimicking Lung Malignancy","authors":"Joon-Suk Choi, I. Oh, Y. Choi, Yong-Soo Kwon, K. S. Kim, S. Lim, Young-chul Kim","doi":"10.6058/JLC.2009.8.2.118","DOIUrl":"https://doi.org/10.6058/JLC.2009.8.2.118","url":null,"abstract":"A 50-year-old m an was adm itted to our hospital w ith a com plaint of blood-tinged sputum . Chest com puted tom ography (CT) showed a 37 m m sized heterogeneously lobulated enhancing mass in the central aspect of the left upper lobe and this m ass was abutting the adjacent m ediastinum (Fig. 1). There was either a focal fibrotic pleural thickening or fissural thickening adjacent to the pulmonary mass. Conglomerated enlarged lymph nodes were observed in the left paraaortic and left anterior cardiophrenic angle areas. 18-Fluorodeoxyglucose positron em ission tom ography dem onstrated hyperm etabolic activity in the left upper lobe and the right thyroid gland (Fig. 2). The pathology of the fine needle aspiration from the thyroid gland revealed papillary carcinom a. Since prim ary or m etastatic lung cancer could not be ruled out, video-assisted thoracic surgery was perform ed. The m icroscopic findings dem onstrated num erous eosinophil infiltrations and m any eggs of paragonimiasis westermani, which were observed in the necrotized granuloma area (Fig. 3). He was underwent subtotal thyroidectom y. M oreover, he subsequently received iodine ablation therapy due to papillary carcinoma with regional lym ph node invasion. (J Lung Cancer 2009;8(2):118󰠏119)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"8 1","pages":"118-119"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2009.8.2.118","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71160196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combining Erlotinib with Cytotoxic Chemotherapy May Overcome Resistance Caused by T790M Mutation of EGFR Gene in Non-Small Cell Lung Carcinoma 厄洛替尼联合细胞毒化疗可克服非小细胞肺癌EGFR基因T790M突变引起的耐药

Journal of lung cancer Pub Date : 2009-12-01 DOI: 10.6058/JLC.2009.8.2.92

I. Oh, K. S. Kim, Ju-yeon Jeong, Hyun-Ju Cho, Young-chul Kim

{"title":"Combining Erlotinib with Cytotoxic Chemotherapy May Overcome Resistance Caused by T790M Mutation of EGFR Gene in Non-Small Cell Lung Carcinoma","authors":"I. Oh, K. S. Kim, Ju-yeon Jeong, Hyun-Ju Cho, Young-chul Kim","doi":"10.6058/JLC.2009.8.2.92","DOIUrl":"https://doi.org/10.6058/JLC.2009.8.2.92","url":null,"abstract":"Purpose: T790M is a mechanism underlying acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We hypothesized that a synergistic combi nation of cytotoxic drugs and EGFR- TKIs m ay overcome resistance. Materials and Methods: The antiproliferative effects and cell cycle distributions followi ng treatm ents w ith Erlotinib (E) and cytotoxic drugs (C) were studied using a lung cancer cell line (NCI-H1975) harboring tw o m utations (L858R and T790M) in the EGFR gene. The cell viability assay and cell cycle analysis were conducted via an MTT assay and flow cytometry. The results of the treatments in different sequences were assessed using the com bination index. Results: Antagonisms w ere noted w hen erlotinib w as administered before cytotoxic drugs (EC sequence), whereas synergisms were observed w hen pre-treatm ent w ith cytotoxic drugs w as admi nistered before erlotinib (C E sequence). Treatm ent in the EC sequence arrested the cells in G 0/G 1 phase and reduced the apoptotic fraction. H owever , treatm ent in the CE sequence arrested the cells in the G2/M and S phase and a trend toward higher fractions of apoptotic cell death was observed.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"8 1","pages":"92-98"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2009.8.2.92","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71160435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Immunohistochemical Assessment of Peripheral Squamous Lung Cancer: Comparison to Central Squamous Cell Carcinoma and Peripheral Adenocarcinoma 外周鳞癌的免疫组化评价:与中央鳞癌和外周腺癌的比较

Journal of lung cancer Pub Date : 2009-12-01 DOI: 10.6058/JLC.2009.8.2.99

J. Kim, J. Park, Young-Pil Wang

{"title":"Immunohistochemical Assessment of Peripheral Squamous Lung Cancer: Comparison to Central Squamous Cell Carcinoma and Peripheral Adenocarcinoma","authors":"J. Kim, J. Park, Young-Pil Wang","doi":"10.6058/JLC.2009.8.2.99","DOIUrl":"https://doi.org/10.6058/JLC.2009.8.2.99","url":null,"abstract":"Purpose: Incidence of peripheral squamous cell carcinoma (pSCCs) of the lung has increased over recent years, but the immunohistochemi cal factors involved in pSCCs have not been well established. The aim of this study was to analyze the immunohistochemi cal differences between pSCCs and central-type SCCs (cSCCs), and similarities between pSCCs and peripheral adenocarcinomas (pADCs). Materials and Methods: In this retrospective study, w e investigated the expression of three potential prognostic factors (p53, Ki-67, t-C EA), and tw o potential therapeutic targets (epiderm al growt h factor receptor [EGFR], and c-erbB-2) in 263 surgically resected cases of primary SCC and pADCs of the lung from January 2001 to July 2008. We divided the SCCs between peripheral and central types, and compared the expression rates of markers between pSCCs and cSCCs, and between pSCCs and pADCs. Results: In this study, there were 149 pADC cases, and among the 114 SCC cases, there were 41 pSCCs (36.0%). There were significantly higher expression rates of Ki-67 and EGFR in pSCCs than in cSCCs or pADCs (p=0.003, p=0.039, respectively). Conclusion: We found immunohistochemical differencies in pSCCs from cSCCs and pADCs. (J Lung Cancer 2009;8(2):99 �� 102)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"8 1","pages":"99-102"},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2009.8.2.99","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71160533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0